David Graham

David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify the risk of liver damage from Pfizer’s diabetes drug Rezulin — which eventually was withdrawn from the market. In 2004, he emerged as…

Read More
zyrem.jpg

"I’m as big a fan of the 1st Amendment as anyone, but this decision strikes me as fundamentally flawed.  We’re not talking about a right to express yourself. We’re talking about selling stuff — stuff that could harm or even kill you if used improperly."  David Lazarus, LA Times

Read More

An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and  taxpayers are saddled with the high cost  through Medicaid and Medicare.

Read More

New FDA antipsychotic Warnings:  "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding."

Read More

According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’ safety hazzards were documented over…

Read More

"The vote is an enormous blow to Avandia and GlaxoSmithKline. The vast majority of panel members voted either to withdraw the drug or to allow continued sales only if strict controls are added"

Read More